Copy to clipboard 
Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% vs. the prior year.
| 3Q17 | 3Q16 | $ Change | % Change | |
| Orthobiologics | $9.9 | $8.3 | $1.6 | 19.3% |
| 9Mo17 | 9Mo16 | $ Change | % Change | |
| Orthobiologics | $27.8 | $26.1 | $1.7 | 6.5% |
This is the company’s first quarter following the discontinuation of Carticel sales in the U.S. The $9.9MM logged is derived entirely from sales of MACI autologous cultured chondrocytes on porcine collagen membrane: a third-gen implant for the repair of symptomatic, full-thickness adult knee cartilage defects.
Leadership estimates the target MACI audience to be about 500 physicians. To date, 440 surgeons are trained on MACI procedures; of those, about half came from former Carticel user and non-Carticel user segments.
Under 10% of the potential patient population is currently penetrated. Medical benefit policies are updated to include MACI, and the number of covered lives is about equal to the number of lives covered by Carticel. Biopsies, an important indicator of adoption and growth, have grown 27% year-to-date, and manufacturing capacity is on-track to be well-covered. With this runway, the company is expanding its salesforce from 28 to 40 reps, who should be trained by the end of 1Q18.
Source: Vericel Corporation
Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% vs. the prior year.
Q17
3Q16
$ Change
% Change
Orthobiologics
$9.9
$8.3
$1.6 ...
Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% vs. the prior year.
| 3Q17 | 3Q16 | $ Change | % Change | |
| Orthobiologics | $9.9 | $8.3 | $1.6 | 19.3% |
| 9Mo17 | 9Mo16 | $ Change | % Change | |
| Orthobiologics | $27.8 | $26.1 | $1.7 | 6.5% |
This is the company’s first quarter following the discontinuation of Carticel sales in the U.S. The $9.9MM logged is derived entirely from sales of MACI autologous cultured chondrocytes on porcine collagen membrane: a third-gen implant for the repair of symptomatic, full-thickness adult knee cartilage defects.
Leadership estimates the target MACI audience to be about 500 physicians. To date, 440 surgeons are trained on MACI procedures; of those, about half came from former Carticel user and non-Carticel user segments.
Under 10% of the potential patient population is currently penetrated. Medical benefit policies are updated to include MACI, and the number of covered lives is about equal to the number of lives covered by Carticel. Biopsies, an important indicator of adoption and growth, have grown 27% year-to-date, and manufacturing capacity is on-track to be well-covered. With this runway, the company is expanding its salesforce from 28 to 40 reps, who should be trained by the end of 1Q18.
Source: Vericel Corporation
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
